Skip to main content

sacubitril; valsartan

Generic: SACUBITRIL; VALSARTAN·Brand: ENTRESTO, ENTRESTO SPRINKLE, SACUBITRIL AND VALSARTAN

sacubitril; valsartan: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.

sacubitril; valsartan evidence translation

What we can confirm

1 FDA record · 1 tracked trial

What it means

Source-backed records connect sacubitril; valsartan to NVS; that link alone does not prove the drug works.

What to watch

Watch active trials and any change in FDA or trial status.
BioSniper AIPage evidence connected

Prepared research question

How could sacubitril; valsartan → NVS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Hypertension

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Novartis AG (NVS)
Hypertension
Approved
Clinical Trials (1)

Special Drug Use Surveillance of Entresto Tablets (Hypertension, CLCZ696A1402): ENLIGHT

NCT05976230·NVS
Completed

Primary endpoint: Percentage of patients with hypotension, hyperkalemia, and renal impairment/failure

Observational1,125 enrolledStarted 2023-09Completion 2025-0550 sites · JapanNovartis Pharmaceuticals
FDA Decisions1 records
Approval(NVS)FDA ↗
NDA218591Type 3 - New Dosage FormStandardOralCapsule, Pellets

Frequently asked questions

Who is developing sacubitril; valsartan?

sacubitril; valsartan is being developed by Novartis AG.

How many clinical trials involve sacubitril; valsartan?

BioSniper tracks 1 clinical trial involving sacubitril; valsartan.

What is sacubitril; valsartan's latest FDA decision?

The most recent tracked FDA decision for sacubitril; valsartan is Approval, dated April 12, 2024.